JP2023527153A5 - - Google Patents
Info
- Publication number
- JP2023527153A5 JP2023527153A5 JP2022570474A JP2022570474A JP2023527153A5 JP 2023527153 A5 JP2023527153 A5 JP 2023527153A5 JP 2022570474 A JP2022570474 A JP 2022570474A JP 2022570474 A JP2022570474 A JP 2022570474A JP 2023527153 A5 JP2023527153 A5 JP 2023527153A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- composition according
- salt
- 25hc3s
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029361P | 2020-05-22 | 2020-05-22 | |
| US63/029,361 | 2020-05-22 | ||
| US202063030207P | 2020-05-26 | 2020-05-26 | |
| US63/030,207 | 2020-05-26 | ||
| US202063113116P | 2020-11-12 | 2020-11-12 | |
| US63/113,116 | 2020-11-12 | ||
| US202163146555P | 2021-02-05 | 2021-02-05 | |
| US63/146,555 | 2021-02-05 | ||
| PCT/US2021/033743 WO2021237143A1 (en) | 2020-05-22 | 2021-05-21 | Treatment of non-alcoholic steatohepatitis (nash) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527153A JP2023527153A (ja) | 2023-06-27 |
| JP2023527153A5 true JP2023527153A5 (enExample) | 2024-05-28 |
Family
ID=78707644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570474A Pending JP2023527153A (ja) | 2020-05-22 | 2021-05-21 | 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230181601A1 (enExample) |
| EP (1) | EP4153164A4 (enExample) |
| JP (1) | JP2023527153A (enExample) |
| KR (1) | KR20230015939A (enExample) |
| CN (1) | CN115916181A (enExample) |
| AU (1) | AU2021273936A1 (enExample) |
| BR (1) | BR112022022737A2 (enExample) |
| CA (1) | CA3195103A1 (enExample) |
| MX (1) | MX2022014575A (enExample) |
| TW (1) | TW202210081A (enExample) |
| WO (1) | WO2021237143A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298681A (en) | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| CN115103591B (zh) | 2019-12-27 | 2026-06-19 | 度勒科特公司 | 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法 |
| CA3187310A1 (en) | 2020-06-26 | 2021-12-30 | Durect Corporation | Use of oxygenated cholesterol sulfates for treating autoimmune conditions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| WO2006047022A1 (en) * | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US8399441B2 (en) * | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| US9034859B2 (en) * | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| CA2848711C (en) * | 2011-09-16 | 2019-08-06 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| KR20150127599A (ko) * | 2013-03-15 | 2015-11-17 | 모치다 세이야쿠 가부시키가이샤 | 비알코올성 지방간염을 치료하기 위한 조성물 및 방법 |
| IL298681A (en) * | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| WO2018026837A1 (en) * | 2016-08-02 | 2018-02-08 | Durect Corporation | Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride |
| CA3058542A1 (en) * | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| CN111182904A (zh) * | 2017-10-06 | 2020-05-19 | 吉利德科学公司 | 包含acc抑制剂的组合治疗 |
-
2021
- 2021-05-21 JP JP2022570474A patent/JP2023527153A/ja active Pending
- 2021-05-21 WO PCT/US2021/033743 patent/WO2021237143A1/en not_active Ceased
- 2021-05-21 MX MX2022014575A patent/MX2022014575A/es unknown
- 2021-05-21 KR KR1020227043976A patent/KR20230015939A/ko active Pending
- 2021-05-21 TW TW110118457A patent/TW202210081A/zh unknown
- 2021-05-21 CN CN202180049351.XA patent/CN115916181A/zh active Pending
- 2021-05-21 AU AU2021273936A patent/AU2021273936A1/en active Pending
- 2021-05-21 EP EP21808175.0A patent/EP4153164A4/en active Pending
- 2021-05-21 BR BR112022022737A patent/BR112022022737A2/pt not_active Application Discontinuation
- 2021-05-21 US US17/924,101 patent/US20230181601A1/en active Pending
- 2021-05-21 CA CA3195103A patent/CA3195103A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526418A5 (enExample) | ||
| KR101465715B1 (ko) | 심혈관 이벤트 발병 예방용 조성물 | |
| HRP20250797T1 (hr) | Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom | |
| JP2022177142A5 (enExample) | ||
| RU2008144136A (ru) | Твердая пероральная лекарственная форма, содержащая усилитель | |
| JP2012176987A (ja) | 脂質療法用のオメガ−３脂肪酸類及び異常脂質血症薬剤 | |
| RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
| US6673831B1 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
| JP2008291034A (ja) | コレステロール吸収阻害剤、ＨＭＧ−ＣｏＡレダクターゼ阻害剤および安定化剤を含有する組成物 | |
| JP2024507810A5 (enExample) | ||
| JP2018508551A5 (ja) | 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物 | |
| JP2023538522A5 (enExample) | ||
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| IL310115A (en) | Treatment of his hyporesponders | |
| IL274414B1 (en) | Oral rifamycin sv compositions | |
| US20140314844A1 (en) | Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability | |
| JP2009515816A (ja) | フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法 | |
| CN100502870C (zh) | 含有瑞舒伐他汀或匹伐他汀和b族维生素的药物组合物 | |
| US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
| WO2020028124A1 (en) | NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS | |
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| KR101830977B1 (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 | |
| CN102416015B (zh) | 一种含他汀类药物的组合物及其用途 | |
| Brinton | Newer HMG‐CoA reductase inhibitor (statin) therapies | |
| TW200404533A (en) | Blood lipid ameliorant compositions |